PASG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. PASG is showing bearish momentum (MACD histogram negative and expanding) with weak fundamentals (no revenue and losses widening in 2025/Q3). While the stock looks oversold and is bouncing pre-market (+3.08% to 11.06) just above key support (10.70), there is no Intellectia edge today (no AI Stock Picker or SwingMax entry) and no near-term news catalyst. For an impatient trader who won’t wait for optimal entries, the risk/reward is unfavorable today—better to stay on the sidelines unless it reclaims the pivot (12.94) with improving momentum.
Trend/momentum: Bearish. MACD histogram at -0.643 and negatively expanding suggests downside momentum is strengthening rather than stabilizing. Overbought/oversold: RSI_6 at 22.9 indicates oversold conditions (short-term), which can produce sharp bounces, but oversold alone is not a buy signal without confirmation. Moving averages: Converging MAs indicates compression/indecision, but with MACD weakening, the bias remains down. Key levels: Immediate support S1 ~10.695 (price 11.06 pre-market is only slightly above it); deeper support S2 ~9.307. Upside hurdles: pivot ~12.941 (first meaningful reclaim level), then R1 ~15.187. Pattern-based forward look: Similar-pattern stats imply a modest bearish skew near-term (40% chance to -2.18% next day), with only small expected gains over week/month, which does not justify chasing a pre-market bounce.
with Buy and a high $68 price target, highlighting PBFT02 gene therapy platform potential.
imply rallies may be sold.
Latest quarter: 2025/Q3. Revenue: 0 (no growth base; still pre-commercial). Profitability: Net income fell to -$7.75M (down ~59.9% YoY), EPS -2.44 (down ~61.0% YoY), indicating worsening losses versus last year. Takeaway: Financial trend is negative (larger losses) with no revenue offset—this weakens the case for an impatient entry without a strong technical trigger or catalyst.
Recent rating/target trend: One notable change—Lucid Capital initiated coverage on 2025-11-24 with a Buy rating and a $68 price target. Wall Street pros view: High upside optionality tied to PBFT02 and the gene therapy thesis. Wall Street cons view: The target is thesis-driven and far from current price; without new clinical/partnering catalysts and with losses widening, the stock can remain volatile and technically weak. Influential/political trading: No recent congress trading data available; no politician/influential buying/selling signal identified in the provided data.
